Concepedia

Edward Mayerson

EM

Statistics

Publications

10

Citations

705

H-Index

10

Active since

2016

Affiliations

Northwestern University(Current)

SWOG Cancer Research Network

National Cancer Institute

Fred Hutch Cancer Center

Cancer Research And Biostatistics

Edward Mayerson is an author at Northwestern University specializing in oncology, cancer immunotherapy, and checkpoint inhibitor therapy.

Publications per year

2016–2023

10

Publications

10

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Sandip Pravin Patel, Megan Othus, Young Kwang Chae et al. · Clinical Cancer Research · 2020 · 326 citations · Full text

, , +17

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Megan Othus, Sandip Pravin Patel, Chris Ryan et al. · Journal for ImmunoTherapy of Cancer · 2021 · 159 citations · Full text

, , +17

A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort

Sandip Pravin Patel, Edward Mayerson, Young Kwang Chae et al. · Cancer · 2021 · 112 citations · Full text

, , +17

Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36).

Sylvia Adams, Megan Othus, Sandip Pravin Patel et al. · Journal of Clinical Oncology · 2020 · 32 citations

, , +17

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.

Ulka N. Vaishampayan, Catherine M. Tangen, Abhishek Tripathi et al. · Journal of Clinical Oncology · 2022 · 17 citations

, , +17

1–5 of 10